Mochi Health and Tirzepatide: The Dual-Agonist Molecule

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

In the PlexusDx Education Hub, this piece narrows in on tirzepatide — a dual-agonist molecule — and how a telehealth program dispenses it. Browse all Peptides & GLP-1 education

This is an independent editorial review. PlexusDx has no financial relationship, affiliate agreement, or sponsorship with Mochi Health of any kind.

Tirzepatide behaves differently from the single-target GLP-1 agonists, and that difference is worth understanding before you pair it with any telehealth program. This review stays on the compound: its mechanism, how a service routes it, and how compounded and branded forms compare. Context reflects April 2026; verify current specifics on the brand's own site.

Tirzepatide as a dual GIP and GLP-1 agonist

Tirzepatide is not a plain GLP-1 agonist. It activates two incretin receptors — GIP and GLP-1 — which is why it is described as a dual agonist. That combined action is the mechanistic feature that separates it from semaglutide-class molecules, and it is the reason the compound is often discussed on its own rather than lumped in with single-target agonists.

How Mochi Health handles a tirzepatide prescription

The workflow mirrors other telehealth GLP-1 pathways: an intake form, a licensed clinician's eligibility review, and a prescription routed to either a retail pharmacy for a brand product or a 503A compounding pharmacy for compounded tirzepatide, followed by titration support. Mochi Health positions itself as telehealth plus insurance support. Confirm the current dispensing route on Mochi Health's official website.

Compounded tirzepatide and the 503A pathway

When a brand product is not the chosen route, compounded tirzepatide is prepared by a 503A pharmacy for an individual patient where clinically appropriate and permitted. This is distinct from an FDA-approved manufactured product in oversight and presentation. Supply conditions and regulatory status for compounded GLP-1s can shift, so any compounding arrangement should be treated as subject to change and verified at the source.

What the SURMOUNT trials measured

Tirzepatide's weight-management evidence draws on the SURMOUNT program (NEJM, 2022), and a related trial, SURMOUNT-OSA (NEJM, 2024), examined obstructive sleep apnea outcomes. Populations and endpoints differed across studies, and individual results vary. The trial record describes averages under study conditions, not a guaranteed outcome for any one person on a prescription.

Why two people respond to tirzepatide differently

Identical prescriptions can produce different experiences, and part of the reason is genetic. Variants in GLP1R (one of tirzepatide's two receptor targets), FTO, MC4R, and TCF7L2 shape appetite, energy balance, and glucose regulation before the first dose. These are pathway-level markers; they do not predict how you will respond to tirzepatide, but they map the biology a dual agonist acts on. The Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights so that terrain is understood upfront. PlexusDx offers tirzepatide and semaglutide directly through its Weight Management Protocols.

No affiliation: PlexusDx is not connected to Mochi Health and had no involvement with any company named in this review.

More from the PlexusDx Education Hub: Alternatives For Mounjaro, Cheap Mounjaro, Cheapest Mounjaro, Discount Mounjaro.

Disclaimer: This article is educational. PlexusDx is not affiliated with Mochi Health and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Frequently Asked Questions

How is tirzepatide different from semaglutide?

Tirzepatide activates two incretin receptors, GIP and GLP-1, whereas semaglutide targets GLP-1 alone. That dual-agonist mechanism is why the two are discussed separately. Both are titrated, prescription-only therapies, and the right choice for any individual is a clinical decision made with a licensed provider.

Does Mochi Health dispense compounded or branded tirzepatide?

Depending on eligibility, insurance, and supply, telehealth programs in this model may route either a brand product through a retail pharmacy or compounded tirzepatide through a 503A pharmacy. The specific path is set during clinical review, so confirm the current arrangement on the brand's own site before enrolling.

Can a genetic test predict how I will respond to tirzepatide?

No. The Precision Peptide Genetic Test does not predict drug response. It analyzes pathway-level variants such as GLP1R and MC4R that describe your baseline appetite and glucose biology, offering context for a discussion with your provider rather than any forecast of tirzepatide results.

What did SURMOUNT-OSA look at?

SURMOUNT-OSA (NEJM, 2024) studied tirzepatide in the context of obstructive sleep apnea, a separate endpoint from the weight-focused SURMOUNT trials. Study populations and measures differed, and outcomes vary by individual. Trial findings describe averages under controlled conditions, not a promise for any single patient.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.